Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: May 16, 2014
Context: This filing serves as a regulatory notification regarding a change in director appointments, specifically concerning a Non-Executive Director's external board membership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification and does not contain financial statements or performance data.
Material Changes
Director Appointment: Hans Wijers, a Non-Executive Director of GSK, was appointed as a member of the Supervisory Board of HAL Holding N.V. on May 16, 2014.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's new appointment in conformity with Listing Rule 9.6.14.
Investor Verification Checklist
- Verify the nature of HAL Holding N.V. to assess potential conflicts of interest or strategic implications for GSK.
- Confirm the date of the appointment (May 16, 2014) against GSK's internal governance records.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F or quarterly earnings release for financial metrics.